Close Menu

Admera Health: Omar Karame

Dec 12, 2019

Admera Health has appointed Omar Karame as CFO. Karame was previously CFO of an energy technology company. He also previously spent several years in private equity, venture capital, and investment banking working on healthcare transactions. He received an MBA from the Wharton Business School and BA from Dartmouth College.

More Like This

Feb 24, 2021

Ultivue: Mike Sismour, Mark Rees

Ultivue, a company specializing in multiplex biomarker assays for tissue phenotyping and digital pathology, has appointed Mike Sismour as vice president, research, and Mark Rees as vice president, corporate development.

Sismour most recently served as chief scientist/head of genomics R&D at Beckman Coulter Life Science. He was a National Institutes of Health Ruth L. Kirschstein postdoc at Harvard Medical School and a fellow at Harvard's Wyss Institute.

Rees most recently worked for StatLab where he helped create a diagnostic division. He previously held leadership roles in commercial development, scientific affairs, and R&D at Enzo Life Sciences, Leica Biosystems (Danaher), and Novocastra Laboratories.

Feb 23, 2021

908 Devices: Jeff George, Fenel Eloi

Mass spectrometry firm 908 Devices has appointed Jeff George and Fenel Eloi to its board of directors.

George has previously served as the global division head and CEO of two divisions of Novartis, Sandoz, and Alcon from 2008 to 2016. In parallel, he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharmaceutical, Dorian Therapeutics, and Wishbone Medical.

Eloi previously served as CFO then COO at Cell Signaling Technology. He also serves on the board of directors of MitoTherapeutix.

Feb 23, 2021

ImmunoScape: Geoff Nosrati

Singapore-based immune profiling company ImmunoScape has named Geoff Nosrati as chief business officer in conjunction with the establishment of the firm's US headquarters in San Diego. Before joining ImmunoScape, Nosrati advised biotechnology clients at McKinsey & Co. He also held senior executive positions at Aduro Biotech. Nosrati holds a PhD in biochemistry and molecular biology from the University of California, Los Angeles.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

Feb 19, 2021

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.

Feb 19, 2021

Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.

Feb 18, 2021

Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.

Feb 18, 2021

Delfi Diagnostics: Tara Maddala, Allison Ryan

Delfi Diagnostics has appointed Tara Maddala as its VP of clinical development and Allison Ryan as VP of data science. Maddala previously served as VP of biostatistics and data managment at Grail. Ryan previously served as VP of data science at Natera. 

Feb 17, 2021

Seer: Deep Nishar, Mostafa Ronaghi

Proteomics company Seer has appointed Deep Nishar and Mostafa Ronaghi to its board of directors. Nishar is a senior managing partner at SoftBank Investment Advisers. Prior to that, he was senior VP of products and user experience at LinkedIn and held senior executive roles at Google. He is also the founder of enterprise software company Patkai Networks.

Ronaghi is the former chief technology officer, senior VP of entrepreneurial development, and senior VP of Illumina. He is also a cofounder of Grail, the Illumina Accelerator, Avantome, NextBio, ParAllele Bioscience, and Pyrosequencing, as well as a current scientific advisory member of Seer.

Feb 16, 2021

NephroSant: Mark Capone

Mark Capone has joined the board of directors of NephroSant, a spinout from the University of California, San Francisco that is developing noninvasive testing solutions for kidney health. He is the president and CEO of Precision Medicine Advisors. Before that, he was president and CEO of Myriad Genetics, and prior to that, he held various positions at Eli Lilly. Capone holds a BS in chemical engineering from Penn State University and an MS in chemical engineering and in management from the Massachusetts Institute of Technology.

Feb 16, 2021

1health: Mostafa Ronaghi

Testing-as-a-service company 1health has appointed Mostafa Ronaghi to its board of directors. Ronaghi was chief technology and senior vice president at Illumina for about 13 years. He also cofounded the Illumina Accelerator and spinoff company Grail. Ronaghi also cofounded several other genomics and life science data ventures, including Avantome, ParAllele Bioscience, NextBio, and Pyrosequencing. Prior to these ventures, he was a principal investigator at Stanford University from 1999 to 2008, focusing on the development of molecular diagnostic applications.

Feb 12, 2021

LexaGene: Daryl Rebeck, Stephen Mastrocola

LexaGene said this week that Daryl Rebeck will resign from the company's board and his position as president effective Feb. 15. The company also said that Stephen Mastrocola has joined the board of directors. Mastrocola recently retired from Ernst & Young after 19 years, where he was a senior assurance partner and led the firm's New England Assurance Practice for several years. Prior to this, he was an assurance partner at Arthur Andersen.

Feb 11, 2021

GenomSys: Alessio Ascari

GenomSys has hired longtime digital health consultant Alessio Ascari as CEO. Ascari joins the Lausanne, Switzerland-based bioinformatics startup after running his own consultancy as well as leading a digital therapeutics startup that helps patients manage blood pressure. He is a former leader of McKinsey's global mobile health initiative. 

Feb 11, 2021

Sophia Genetics: Ross Muken

Sophia Genetics has named Ross Muken as chief financial officer. Muken, who has more than two decades of experience in finance, previously had been CFO and COO of Click Therapeutics. He has also had stints as head of healthcare services and technology research at Evercore ISI and in equity research at Thomas Weisel Partners. 

Feb 10, 2021

Sema4: Nat Turner, Emily Leproust, Eli Casdin

Sema4 has appointed three new members to its board of directors, who will take up their posts after the firm has gone public through a planned merger with special purpose acquisition company CM Life Sciences.

The new members are Nat Turner, cofounder and CEO of Flatiron Health; Emily Leproust, cofounder and CEO of Twist Bioscience; and Eli Casdin, founder and chief investment officer of Casdin Capital.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.